Edwards Lifesciences Corp (EW) is a globally recognized medical technology company committed to innovating cardiovascular disease treatment. Since its establishment in 1958, the company has played a seminal role in transforming cardiac health, particularly through developing transcatheter heart valves. Headquartered in Irvine, California, Edwards Lifesciences stakes its claim as the worldwide leader in patient-focused medical innovations for structural heart disease and critical care monitoring.
The company’s history is woven with milestones that have revolutionized cardiac treatments. It all began with their artificial heart valve, which heralded a new era of cardiac surgery. In recent years, Edward Lifesciences introduced the SAPIEN 3 transcatheter aortic valve, yet another medical breakthrough which has greatly improved patients' quality of life and eliminated the need for open-heart surgery in certain cases.
Edwards Lifesciences operates under four main business units: Transcatheter Heart Valves, Surgical Structural Heart, Critical Care, and Advanced Surgical Technologies. Each unit is dedicated to providing novel solutions that transform patient outcomes, reduce hospitalizations, and decrease healthcare costs.
The culture at Edwards Lifesciences emphasizes teamwork and innovation. The company's workforce comprises a diverse group of individuals who are passionate about their work and dedicated to delivering quality medical solutions. They adhere to a strict code of conduct, and their approach to sustainability involves a commitment to reducing environmental impact, promoting human rights, and creating economic value.
Financially, Edwards Lifesciences has demonstrated stable performance and steady growth, benefiting from its dedication to innovation and quality. In 2020, despite the challenges of the COVID-19 pandemic, the company achieved sales of approximately $4.3 billion.
The company also places significant emphasis on philanthropy by helping to address global disparities in heart valve disease treatment through the Edwards Lifesciences Foundation. The Foundation has committed more than $50 million since 2014 in grants to organizations and projects around the world that are helping to improve patient care, support education and provide community support.
In a nutshell, Edwards Lifesciences Corp is not just a medical technology company; it is a symbol of hope for millions of people worldwide battling cardiovascular disease. Their commitment to innovative, life-saving technology, coupled with their dedication to corporate responsibility, makes them a leader in their field and a shining example of how corporations can impact global health.